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Abstract: Malignant gliomas are primary brain tumors with poor prognoses. These tumors are infiltrated
by brain intrinsic microglia and peripheral monocytes which promote glioma cell invasion. In our previous
studies, we discovered that the activation of Toll-like receptor 2 (TLR2) on microglia/brain macrophages
converts them into a protumorigenic phenotype through the induction of matrix metalloproteinases (MMP)
9 and 14. In the present study, we used in vitro and in situ microglia-glioma interaction experimental
models to test the impact of a novel inhibitor of TLR 2, ortho vanillin (O-Vanillin) to block TLR2 mediated
microglia protumorigenic phenotype. We demonstrate that O-Vanillin inhibits the TLR2 mediated
upregulation of MMP 9, MMP 14, IL 6 and iNOS expression. Similarly, the glioma supernatant induced
MMP 9 and MMP 14 expression in murine and human microglia is abrogated by O-Vanillin treatment.
O-Vanillin is not toxic for microglia, astrocytes or oligodendrocytes. Glioma growth in murine brain slice
cultures is significantly reduced after treatment with O-Vanillin, and this reduced glioma growth depends
on the presence of microglia. In addition, we also found that O-Vanillin inhibited the glioma induced
proliferation of murine primary microglia. In summary, O-Vanillin attenuates the pro-tumorigenic
phenotype of microglia/brain macrophages and thus qualifies as a candidate for glioma therapy.
Keywords: microglia; glioma; therapy; tumor microenvironment; TLR2
1. Introduction
Primary malignant brain tumors remain a devastating tumor entity characterized by poor prognoses
despite extensive research and gains in knowledge concerning its genesis and progression [1]. Microglia,
the innate immune cells of the brain and infiltrating monocytes/macrophages play a pivotal role in glioma
promotion and growth and contribute to the tumor tissue by up to 30% of the cells [2]. Glioma induces the
polarization of glioma associated microglia/macrophages (GAMs) into a glioma-supporting phenotype
through complex interactions involving several signaling mechanisms [3]. One major mechanism that
contributes to glioma invasiveness is the degradation of the surrounding extracellular matrix by matrix
metalloproteases (MMPs). MMPs are a group of enzymes that proteolytically cleave diverse proteoglycans,
collagens and gelatin [4]. We discovered that microglial cells express MMP14 as a membrane bound protein
which serves to activate glioma released MMP2. While microglia in the healthy brain do not express
MMP14, it is upregulated in glioma associated GAMs. This upregulation is induced by versican released
from glioma cells which signals via toll like receptor 2 (TLR2). This interaction between glioma and GAMs
is an important contributor to microglia/macrophage-induced glioma invasiveness und progression [5,6].
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TLRs are membrane-bound receptors that recognize a broad spectrum of pathogen-associated molecular
patterns. In addition, TLRs can be activated by endogenous ligands such as versican and tenascin C [7]. In the
glioma context, TLR4 and in particular TLR2 are mediators of glioma-GAM interactions. The expression of
TLR2 and MMPs in glioma tissue was found to be inversely correlated with patients’ median survival
according to TCGA analysis. In our previous study, we demonstrated that the downregulation of TLR2
in microglia by minocycline treatment correlates with the downregulation of MMP14 and increased
survival of brain tumor bearing mice [5]. Recently, Mistry et al. [8] identified a loop within the intracellular
adapter domain of TLR2 that can be blocked by O-Vanillin, and thus identified O-Vanillin as an TLR2
inhibitor. O-Vanillin is an isomer of the well-known food supplement vanillin and was studied in different
malignancies including colon, ovarian and lung cancer and melanoma [9–11]. So far, the use of O-Vanillin
as a potential drug in gliomas has not yet been explored.
In the present study, we tested whether O-Vanillin can be used to inhibit glioma-induced TLR2
signaling in murine microglia. O-Vanillin was able to attenuate the glioma-induced increase in mmp14
and mmp9 in cultured microglia as well as in microglia/macrophages isolated from human glioma
samples. Moreover, O-Vanillin also attenuated the growth of gliomas injected into murine brain slice
cultures and this effect was dependent on the presence of microglia.
2. Results
2.1. Vanillin Blocks TLR2 Mediated Signaling in Microglia
To analyze O-Vanillin’s potential as inhibitor of TLR2 signaling in microglia, we stimulated primary
cultured microglia cells with the TLR2 agonists Pam3CSK4 (1 µg/mL) for 6 h and measured the release of
IL-6 by ELISA (Figure 1A) and the increased RNA expression of mmp9 (Figure 1B), mmp14 (Figure 1C) and
inos (Figure 1D) by PCR. Pam3CSK4 significantly increased the release of IL-6 by 46 times and the RNA
expression of mmp9 by 25 times, of mmp14 by 2.5 times and of inos by 35 times. Co-incubation with 100 µM
O-Vanillin reduced the IL-6 levels and the increase in mmp9, mmp14 and inos RNA expression to control
levels (Figure 1), indicating that O-Vanillin is a highly efficient inhibitor of TLR2 in murine microglia.Int. J. Mol. S i. 2020, 21, x FOR PEER REVIEW 3 of 14 
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<0.001 (***). 
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the propidium iodide (PI) incorporation as marker for cell death in a plate reader. Cells were 
incubated for 24 h with 1, 10 and 100 µM O-Vanillin. We did not observe more than 3% differences 
in the PI fluorescence at all O-Vanillin concentrations in all the four cell types (Figure 2A). As a 
positive control, we incubated cells with 10% DMSO, which resulted in a more than 100% increase in 
the number of PI fluorescent cells (Figure 2A). Increasing the exposition time of 100 µM O-Vanillin 
to 48 h did also not affect the number of PI fluorescent microglial cells. To validate these results, we 
also analyzed the PI incorporation in microglial cells after 24h treatment with 1, 10 and 100 µM O-
Vanillin via FACS. Similar to PI fluorescence measured in the plate reader, there was no difference in 
PI positive microglial cells when compared to control (Figure S1). As another assay for cell viability, 
we used the Alamar Blue assay which indicates metabolic activity. After incubation of microglial and 
GL261 cells with 10 and 100 µM O-Vanillin, we measured no significant difference in the Alamar Blue 
assay (Figure 2B). Incubation of microglial cells with 1000 µM O-Vanillin did not have an effect. Only 
GL261 cells incubated for 24 h with 1000 µM O-Vanillin showed decreased metabolic activity (Figure 
2B). 
Figure 1. O-Vanillin abrogates the Pam3CSK4 induce TLR2 stimulation. We sti lated microglial cells
with the TLR2 agonists Pam3CSK4 (1 µg/mL) and with Pam3CSK4 combined with 100 µM O-Vanillin
compared to control in DMEM. We determined relative increase in IL6 by ELISA (A) and mmp9 (B),
mmp14 (C) and inos by qPCR (D) 6 h after stimulation. The panel shows means and SEM from three
independent experiments. Significance was defined at p values < 0.05 (*), <0.01 (**) and <0.001 (***).
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2.2. Vanillin is Not Cytotoxic to Glial Cells and Only at High Doses to Glioma Cells
To test the potential cytotoxicity of O-Vanillin, we evaluated the cell viability of cultured murine
microglia and astrocytes, the oligodendrocyte cell line OLN 93 and GL261 glioma cells by analyzing
the propidium iodide (PI) incorporation as marker for cell death in a plate reader. Cells were incubated
for 24 h with 1, 10 and 100 µM O-Vanillin. We did not observe more than 3% differences in the PI
fluorescence at all O-Vanillin concentrations in all the four cell types (Figure 2A). As a positive control,
we incubated cells with 10% DMSO, which resulted in a more than 100% increase in the number of
PI fluorescent cells (Figure 2A). Increasing the exposition time of 100 µM O-Vanillin to 48 h did also
not affect the number of PI fluorescent microglial cells. To validate these results, we also analyzed
the PI incorporation in microglial cells after 24h treatment with 1, 10 and 100 µM O-Vanillin via
FACS. Similar to PI fluorescence measured in the plate reader, there was no difference in PI positive
microglial cells when compared to control (Figure S1). As another assay for cell viability, we used
the Alamar Blue assay which indicates metabolic activity. After incubation of microglial and GL261
cells with 10 and 100 µM O-Vanillin, we measured no significant difference in the Alamar Blue assay
(Figure 2B). Incubation of microglial cells with 1000 µM O-Vanillin did not have an effect. Only GL261
cells incubated for 24 h with 1000 µM O-Vanillin showed decreased metabolic activity (Figure 2B).Int. J. Mol. Sci. 2020, 21, x FOR PEER REVIEW 4 of 14 
 
 
Figure 2. Vanillin is not cytotoxic to glial cells and only at high doses to glioma cells (A) PI 
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red fluorescence relative to the control in DMEM only. The incorporation of PI did not change due to 
O-Vanillin treatment. Application of 10% DMSO served as a positive control. (B) O-Vanillin reduces 
cell metabolism in glioma GL261 cells but not in microglial cells. Primary murine microglia cells were 
treated with 10, 100, 1000 µM O-Vanillin at the concentrations for 3, 6 and 24 h. The metabolic activity 
of the cells was determined with the Alamar Blue assay. Cells incubated in cell culture medium only 
served as control. No significant alteration in cell metabolism were observed at any condition. In a 
similar approach, the metabolic activity of GL261 glioma cells was analyzed. A significant reduction 
in cell metabolism in comparison to the control group was observed after stimulation with 1000 µM 
O-Vanillin after 24 h of incubation (B). The panel shows means and SEM from three independent 
experiments. Significance was defined at p value < 0.05 (*). 
2.3. O-Vanillin Attenuates the GCM Stimulated Expression of MMP9 and MMP14  
We have previously shown that GCM triggers an increase in mmp9 and mmp14 expression in 
cultured microglia which is mediated by TLR2 signaling [12,13]. We confirmed the increase in mmp9 
Figure 2. Vanillin is not cytotoxic to glial cells and only at high doses to glioma cells (A) PI incorporation
in microglial cells, astrocytes, OLN93 cells and GL261 cells is not affected by treatment with O-Vanillin.
Microglia, astrocytes, ol godendrocytic cell line OLN93 and GL261 we e treat d with O-Vanillin at 1, 10,
100 µM for 24 h. Subsequently, we determined the PI incorporation by measuring red fluorescence relative to
the control in DMEM only. The incorporation of PI did not change due to O-Vanillin treatment. Application
of 10% DMSO served as a positive control. (B) O-V nillin red c s cell metabolism in glioma GL261 cells
but not in microglial cells. Primary murine microglia cells were treated with 10, 100, 1000 µM O-Vanillin at
the concentrations for 3, 6 nd 24 h. The metabolic activity of the cells was determined with the Alamar
Blue assay. Cells incubated in cell culture medium only served as control. No significant alteration in cell
metabolism were observed at any condition. In a similar approach, the metabolic activity of GL261 glioma
cells was analyzed. A significant reduction in cell metabolism in comparison to the control group was
observed after stimulation with 1000 µM O-Vanillin after 24 h of incubation (B). Th panel shows means and
SEM from three independent experiments. Significance was defined at p value < 0.05 (*).
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2.3. O-Vanillin Attenuates the GCM Stimulated Expression of MMP9 and MMP14
We have previously shown that GCM triggers an increase in mmp9 and mmp14 expression in
cultured microglia which is mediated by TLR2 signaling [12,13]. We confirmed the increase in mmp9
and mmp14 expression after a 6 h stimulation of cultured microglia with GCM obtained from the
supernatant of GL261 cells. mmp9 expression was increased to 2.6 and mmp14 to 3.2-fold as determined
with PCR. Co-incubating the microglial cells with GCM and 100 µM O-Vanillin completely abolished
the stimulating effect of GCM on mmp9 and mmp14 expression (Figure 3A,B).
We further confirmed these findings in human glioma associated CD11b+ cells (i.e., glioma
associated microglia and macrophages-GAM). We isolated CD11b+ cells from human glioma samples
and cultivated them for 12 h. The cells were incubated with 100 µM O-Vanillin. The treatment
with O-Vanillin significantly reduced the RNA expression of MMP14 by 26% in GAM (Figure 3C).
The reduction in MMP9 was not significant (Figure 3D).
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Organotypic brain slices were injected with GL261 glioma cells as an experimental model to 
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Figure 3. O-Vanillin significantly reduces the glioma induced increase of the TLR2 downstream targets
mmp9 and mmp14 on RNA level in murine primary icroglia cult s (A,B) and CD11b+ human
GAM (C,D). GCM induced a significant increase in the RNA expression of mmp14 (A) and mmp9 (B) in
murine primary microglia cells with GCM treatment and could inhibit this effect by treating the cells
with 100 µM O-Vanillin for 6 h. (C) and (D) we treated GAM from human glioma samples for 12 h with
O-Vanillin. The expression of MMP14 (C) was significantly reduced by 26%. In D) the reduction in
MMP9 RNA levels after O-Vanillin treatment was not significant. The panel shows means and SEM
from three independent experiments. Significance was defined at p values < 0.05 (*), <0.001 (***) and
n.s. not significant.
2.4. O-Vanillin Reduces Glioma Growth in Organotypic Bra Slices
Organotypic b ain slic s were injected with GL261 glioma cells as n experime al model to quantify
glioma growth. We injected GL261 cells expressing red fluorescent protein mCherry into organotypic
brain slices obtained from mouse cortex 24 h after slice preparation and quantified glioma growth after
120 h by measuring the volume of the fluorescent signal after 3D reconstruction with the Imaris software.
The treatment with 100 µM O-Vanillin during the entire period of 120 h significantly reduced the tumor
volume by 85% compared to an untreated control. When the O-Vanillin treatment was delayed, by either 48
or 72 h, there was no significant reduction in the fluorescent signal (Figure 4A,B).
Int. J. Mol. Sci. 2020, 21, 2959 5 of 13
We have previously shown that microglia promote glioma growth in the organotypic brain
slice model [14]; therefore, we analyzed the effect of O-Vanillin in brain slices depleted of microglia.
By treating the organotypic slices for 24 h with clodronate-filled liposomes, we depleted microglia
as previously described [14]. After a resting period of 72 h, the slices were inoculated with mCherry
Gl261 cells and analyzed after 120 h. As reported previously, the fluorescence volume was reduced by
24% when comparing untreated slices without microglia to slices with microglia. The 120 h treatment
with 100 µM O-Vanillin reduced glioma volume by 38% in microglia containing slices. The tumor
volume was reduced by 65% in OBSC without microglia 120 h after 100 µM O-Vanillin treatment.
Again, the 48 h treatment with 100 µM O-Vanillin did not significantly alter tumor volumes in control
and experimental groups (Figure 4C,D). Please note that the Figure 4B,D do not represent the same
kind of experiments. In Figure 4B, the slices were inoculated 24 h after preparation with mCherry
Gl261 cells, and in Figure 4D, 96 h after preparation, due to the microglia depletion protocol [14].
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Figure 4. O-Vanillin reduced t mor v lume in org otypic brain lices (OBSC) and the reduction is
further enhanced after depletion of microglia. (A) OBSC were treated with 100 µM O-Vanillin for
48 h, 72 or 120 h after inoculation with red fluorescent mCherry GL261 glioma cell line into the slice.
Examples for 3D r construction of tumor spread i each group are hown. (B) Mean tu volume for
all experiments are shown relative to the control. We observed a significant reduction in tumor volume
by 85% in comparison to the control group after 120 h O-Vanillin treatment. Both 72 and 48 h O-Vanillin
treatment did not significantly reduc tumor volume. (C) T investigate whether reduction in tumor
volume after O-Vanillin treatment is microglia dependent, we depleted microglial cells using clodronate
liposomes and treated OBSC with O-Vanillin for 48 and 120 h after inoculation of fluorescent labeled
GL261 murine glioma cells. Examples for 3D reconstruction of tumor spread in each group are shown.
(D) Mean tumor volume for all experiments are shown relative to the control. We observed a significant
reduction in tumor volume by 24% in OBSC’s depleted of microglia, reduction in tumor volume
by 35% after treatment with O-Vanillin without microglia depletion as well as reduction in tumor
volume by 65% after both depletion of microglia and O-Vanillin treatment for 120 h in comparison
to untreated control group. The reduction in tumor volume by 30% after both microglia depletion
and O-Vanillin treatment for 120 h in comparison to the group without microglia depletion but after
treatment with O-Vanillin for 120 h was significant. The panel shows means and SEM from three
independent experiments. Significance was defined at p values < 0.05 (*), <0.01 (**) and <0.001 (***).
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2.5. O-Vanillin Reduces the Glioma-Induced Proliferation of Cultured Microglia
We stimulated murine primary cultured microglia with GCM and measured the proliferation rate
by BrdU incorporation. Application of GCM increased the proliferation rate of microglial cells by 41%
after 24 h (Figure 5). Co-application of 100 µM O-Vanillin inhibited the effect of GCM on microglia
proliferation (Figure 5).
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Figure 5. O-Vanillin significantly reduced glioma induced microglia proliferation.The proliferation rate
was determined by BrdU incubation for 24 h and is shown relative to control. The stimulation with
GCM significantly increased the proliferation by 41%. Co-application of GCM and 100 µM O-Vanillin
normalized the proliferation to control level. The panel shows means and SEM from three independent
experiments. Significance was defined at p value <0.001 (***).
3. Discussion
Glioma cells polarize GAMs into a tumor promoting phenotype and these cells acquire
an expression profile which is distinct from M1 or M2 profile [15]. Their tumor promoting activity
is mediated by an increased production and activation of matrix m tallopr teinases, p r icular
MMP9 and MMP14 [12,13]. Thus, glioma cells exploit GAMs to promot gli ma invasiveness, immune
evasion and survival [3]. TLRs ind ce the glioma-associated phenotype of GAMs. We h ve shown that
the endog nous lig ve sican activates TLR2 in GAMs and is an important pa hway for glioma-GAM
communic tion [12]. The TLR2 pathway h s been established as a tumor promoting component in
different malignan ies like ov ria carcinomas, mel nom s, or glioma [9,16]. The expression f TLR2
in glioma samples, which consists of up to 30% of microgl a/macrophages, is inve se y correlated wit
patients’ verall surv val [6,17]. We a so found a nega ive correlation between MMP14 and MMP9
expr ssion on overall survival [18]. Thus, TLR2 has emerged as a novel target for impairing glioma
growth and we could demonstrate in a m use glioma mode that interfering with TLR2 signaling by
using TLR2—s ecific ant bodies attenu te glioma growth [6].
Mistry et al. identified O-Vanillin using comput r-aided structure analysis as p tential inhibitor
of TLR2 signaling by blocking its heterodimerization. They were able to inhibit the TLR2-mediated
increase in IL8 RNA in peripheral macrophages using O-Vanillin. We adapted these finding to the
context of GAMs. We showed that O-Vanillin is a specific TLR2 inhibitor in primary microglia
(Figure 1). We found that the TLR2 agonist Pam3CSK4 induced an increased mmp9, mmp14, and inos
expression [19–21]. A quantity of 100 µM O-Vanillin was able to inhibit this induction. Moreover,
the increase in MMP9 and MMP14 expression by GCM was also blocked by O-Vanillin. We therefore
conclude that O-Vanillin works as an TLR2 inhibitor in microglia.
To test the impact of O-Vanillin on glioma growth, we used an organotypic slice model in which
we could quantify glioma growth. Treatment of the slices with 100 µM O-Vanillin led to a significant
reduction in tumor volume by 85%. We also tested whether the impact of O-Vanillin was mediated by
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microglia by depleting these cells from the slices. As previously described, there was a reduction in
glioma growth through the depletion of microglia, but treatment with O-Vanillin led even to a further
decrease in glioma growth. This can be explained by our observation that O-Vanillin directly inhibited
glioma growth. As a further mechanism of O-Vanillin action, we observed an inhibitory effect on
microglia proliferation induced by GCM. It is, however, not yet fully explored to what extent and by
which mechanism glioma induce the proliferation of microglia. In contrast to our observation in mice,
conditioned medium from the rat glioma cell line C6 did not alter rat microglial proliferation [21].
Li and Graeber (2012) speculate that gliomas secrete monocyte colony stimulating factor (M-CSF)
which triggers the proliferation of GAM via M-CSF receptor (M-CSFR) [22].
O-Vanillin demonstrated a good tolerability at even high concentrations up to 2 mM on a cellular
level and 100 mg/kg (660 µM) over one month in vivo in rodents without evidence for macroscopic
anomalies or cell death [11,23]. We also tested the effect of O-Vanillin on the survival of oligodendrocytes
using a cell line as a model, primary cultured astrocytes and microglia, and found no impact on cell
viability using the propidium iodide and Alamar Blue assays. At higher concentrations and longer
exposure times, O-Vanillin decreased glioma cell survival while having no impact on the survival
of glial cells. Marton et al. reported that O-Vanillin reduced the growth of a human Melanoma cell
line [10]. We thus identified O-Vanillin as a potential drug to attenuate glioma growth. Since O-Vanillin
was shown to penetrate the blood-brain barrier [24], there should be further studies conducted to
clarify the therapeutic effect of O-Vanillin in vivo.
4. Materials and Methods
4.1. Animals
We made primary microglial cell cultures and organotypic brain slice cultures (OBSC) from
C57/Bl6 wild-type mice (Charles River Laboratories, Wilmington, MA, USA) for all in vitro experiments.
The mice were bred and maintained in the animal housing facility of the Max Delbrück Center as per
ethical rules and approval of the local governmental institutions (01 January 2018; X9005/18; §9 and §11
of German animal protection low). The animals lived according to a 12/12 dark-light rhythm and had
access to water and food ad libitum.
4.2. Cell Culture
Primary microglial cells were cultivated as described previously (Markovic et al., 2005) [14]. Briefly,
the cerebral cortices of newborn C57Bl/6 mice were carefully cleaned of blood vessels and meninges,
then the tissue was enzymatically digested with Trypsin/DNase (Gibco/Life Technologies, Carlsbad,
CA, USA) and mechanically dissociated with a fire-polished glass Pasteur pipette. Cultures were
incubated at 37 ◦C, 5% CO2 humidified atmosphere in complete growth medium (10% fetal calf serum
(FCS)/Dulbecco´s modified Eagles Medium (DMEM with 200 mM glutamine, 100 U/mL penicillin and
100 µg/mL streptomycin all from Gibco/Life Technologies) and the next day adherent cells were washed
5 times with phosphate buffered solution (PBS)(Gibco/Life Technologies). After culturing for one week
followed by culturing with L929 fibroblast cell line (RRID:CVCL_AR58; obtained from American Type
Culture Collection, Manassas, VA, USA) conditioned medium for two days the microglia are now seen
as floating cells or as semi-adherent cells on top of an astrocytic monolayer. These were then harvested
by shaking the culture flask.
4.3. Astrocytes
To generate C57/Bl6 wild type astrocytes, the animals were processed as described above. After the
third microglial shake off, the confluent flasks were washed thoroughly with PBS. Trypsin/EDTA
was used to detach the cells. The reaction was stopped with complete growth medium and the cells
were centrifuged at 500× g for 5 min at 4 ◦C. Then the cells were counted in a Neubauer chamber
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(Paul Marienfeld, Lauda-Koenigshoffen, Germany) according to the manufacturer´s instructions and
plated as required for each experiment.
4.4. Glioma Cell Lines
The GL261 cells (RRID:CVCL_Y003)were obtained from the Jackson Laboratory (Bar Harbor,
ME, USA). The cells were grown in DMEM with 10 % FCS, 200 mM glutamine, 100 U/mL penicillin
and 100 µg/mL streptomycin (all from Gibco/Life Technologies). Red fluorescent mCherry expressing
GL261 glioma cells were generated according to the protocol of Vinnakota et al. [5]. First, we transfected
OmicsLinknontargeted short hairpin RNA tagged with mCherry (GeneCopoeia, Rockville, MD, USA)
according to the manufacturer’s instructions. Transfected GL261 cells were then treated with 5 µg/mL
puromycin (Gibco/Life Technologies) for the selection. After the 15th passage, the cell line was discarded.
4.4.1. OLN93 Oligodendrocyte Cell Line
The immortalized oligodendrocyte progenitor cell line OLN93 (RRID:CVCL_5850; gift from C.
Richter-Landsberg) was passaged in complete growth medium and split when confluent [25,26].
4.4.2. Human Glioma Samples
All human glioma samples were provided by the Department of Neurosurgery, University
Hospital Schleswig-Holstein and Department of Neurosurgery HELIOS Hospital Berlin-Buch. After the
Department for Pathology confirmed the diagnosis of a malignant glioma, the cells were further
processed. All patients were informed and gave their permission for further scientific processing of the
tissue samples. Analysis of resected human brain tumors was performed according to the rules by the
Ethical Committee of University Hospital Kiel (UKSH D447/18) and Charité (EA4/098). Briefly, tumor
tissue was taken during the surgery and was placed immediately in complete growth medium for
cell isolation.
All experiments were performed with Mycoplasma-free cells.
4.4.3. Magnetic Cell Separation (MACS) of Human Brain TumorTissue
Glioma associated brain microglia/macrophages were isolated from the human tumor resected
tissues. Fresh tissue was dissociated immediately after resection using a neural tissue dissociation kit
(MiltenyiBiotec, BergischGladbach, Germany). Erythrocytes were lysed by adding 5 mL ammonium
chloride solution. Thereafter, cells were resuspended in PBS containing 0.5% bovine serum albumin
and 2 mM EDTA. Magnetic sorting for CD11b+ cells was then performed by using CD11b MicroBead kit
(MiltenyiBiotec) following the manufacturer´s instruction. MACS into CD11b negative (Flow-through)
and CD11b positive (CD11b+) enriched cell populations was done using several MACS columns in
series. Both CD11b negative and CD11b+ fractions were collected. A purity check was performed
after MACS by flow cytometry analysis of a small fraction of the sorted populations (BD FACS Aria,
BD Biosciences, San Jose, CA, USA).
4.5. Production of Glioma Conditioned Medium (GCM)
GCM was prepared from the 80% confluent GL261 cultures by cultivation in complete culture
medium overnight. The GCM was collected, briefly centrifuged and sterile-filtered through 0.2 µm
filter mesh (Sartorius Stedim Biotech GmbH, Göttingen, Germany) and applied for further experiments.
Flow Cytometry
For all the flow cytometry analysis, after the treatment or isolation, cells were incubated for 30 min
at 4 ◦C. Before fluorescence activated cell sorting (FACS), cells were stained with 2.5 µg/mL propidium
iodide (Life Technologies) for 15 min. Flow cytometry was done by BD FACS Aria and data were
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analyzed using FlowJo software (Treestar, Ashland, OR, USA). Flow cytometry data were quantified
by mean fluorescence intensity (MFI) and presented in histograms.
4.6. IL-6 ELISA
To investigate how the cytokine release was affected by the O-Vanillin treatment, 20,000 microglial
cells were plated in a 96 well plate (Sarstedt, Nümbrecht, Germany) and maintained overnight. On the
next day the cells were stimulated with Pam3CSK4 (InvivoGen, San Diego, CA, USA) and GCM for 6 h
and treated with 100 µM O-Vanillin (Sigma-Aldrich, St. Louis, MO, USA). LPS (Enzo Life Sciences Inc.,
Farmingdale, NY, USA) was used as a positive control. After stimulation, the medium was discarded
and fresh culture growth medium was added for 12 h. Then the medium was evacuated and stored at
−20 ◦C. The IL-6 ELISA Assay was performed with ELISA Kit (R&D Systems, Minneapolis, MN, USA).
For further experiments the medium was diluted 1:10 in an ELISA Buffer. Prior to the quantification
of IL-6, the 96 well plates were precoated. The capture antibody was diluted in PBS according to
manufacturer´s recommendations and pipetted into a 96-well microplate. The plates were sealed
and incubated overnight. The next day the plates were washed 3 times with washing buffer, blocked
for 1 h and washed again. Then, 100 µL of the diluted sample solution and standard solution were
added to the prepared plates and incubated for 2 h at room temperature. Afterwards, the sample
solutions were aspirated and the plates were washed again 3 times. The detection antibody was added
and incubated for 2 h at room temperature with subsequent aspiration of the antibody and washing.
After incubating the plates with 100 µL of the provided Streptavidin-HRP for 20 min and washing
them again, the substrate solution was added and incubated for 20 min. To stop the reaction, we mixed
50 µL of Stop Solution into each well. The optical density of each well was analyzed using a plate
reader at 450 nm (Infinite M200, Tecan, Männedorf, Switzerland).
4.7. Propidium Iodide (PI) Staining
A total of 20,000 neonatal C57/Bl6 microglial cells, 10,000 astrocytes and 5000 OLN93
oligodendrocytes were plated in different 96-well plates and were left to rest overnight. The next day,
the cells were treated with 100 µM O-Vanillin for 24 or 48 h. Following the incubation period, the
cells were washed with 200 µL PBS. Then, 100 µL complete growth medium containing 2.5 µg/mL
PI (Life Technologies,) was added to stain the DNA of dead cells with permeable cell membranes.
The cells were incubated for 15 min at room temperature and analyzed in a plate reader (Infinite M200,
Tecan) at an excitation wavelength of 530 nm and a frequency of 25 flashes. The emission was analyzed
at a wavelength of 645 nm. The fluorescence intensity of an untreated control group was defined as
100% living cells. As positive control 10 µL DMSO (Sigma-Aldrich) was added to every sample and
the plate was analyzed again after 15 min. The assay was considered as working if the fluorescence
intensity of incorporated PI increased at least twofold.
4.8. Proliferation Assay
To determine the number of proliferating cells, we analyzed the incorporation of blue fluorescent
BrdU (Roche, Basel, Switzerland) into the DNA within 24 h. A total of 20,000 C57/Bl6 microglial cells
were plated in a 96 well plate. Afterwards, the cells were treated with 100 µM O-Vanillin overnight.
On the next morning, the medium was discarded and new complete growth medium containing
fluorescent labeled BrdU and 100 µM O-Vanillin was added. The cells were incubated for another 24 h.
As a negative control we used dead cells after incubation in 10% DMSO for 24 h. As a positive
control we used the well-known inductor of microglia proliferation, mMSCF (PeproTech, Rocky Hill,
CT, USA) [27]. The cells were analyzed in a plate reader (Infinite M200, Tecan). While mMCSF
induced a significant increase in proliferation, the DMSO incubated cells showed no evidence for
BrdU incorporation.
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4.9. Alamar Blue Assay
The metabolism assay Alamar Blue (Alamar Blue Cell Viability Reagent, Thermo Fisher Scientific,
Waltham, MA, USA) was applied for both primary murine neonatal microglia and murine GL 261
cells. Primary murine neonatal microglia were used directly after preparation from newborn C57BL/6
wildtype mice. Murine glioma GL261 cells were harvested from a 25 cm2 cell culture flask (Sarstedt).
The cell number was adjusted to 10,000 cells/mL. Next, the cells were treated with different O-Vanillin
concentrations and incubated for 3, 6 and 24 h. Fresh complete growth medium was added to the
control wells. Finally, all media were replaced by 100 µL of fresh 10% Alamar Blue solution made by
diluting Alamar Blue dye to fresh medium and the cells were incubated for further 3 h at 37 ◦C and
5% CO2. The Alamar Blue absorption spectrum in cells was measured using a plate reader (Infinite
M200). The data was analysed according to the manufacturer´s protocol (Thermo Fisher Scientific,
AlamarBlue Cell Viability Reagent).
4.10. RNA Isolation/qPCR
For all RNA dependent experiments up to 300,000 cells were plated in a 12-well plate (Sarstedt).
The standard treatment regimen was 100 µM O-Vanillin for 6 h. Isolated human CD11B positive cells
were treated for 12 h. Cells were washed in cold PBS (Life technologies) to remove redundant complete
growth medium. The isolation was carried out using a Promega RNA Isolation Kit (ReliaPrep RNA Cell
Miniprep System, Promega, Fitchburg, MA, USA) following manufacturer´s instructions. The isolated
RNA was dissolved in 15 µLRNAse free water (Sigma-Aldrich) and stored at −20 ◦C. The quality
and total amount of RNA was analyzed using a Nano Drop (NanoDrop8000 Spectrophotometer,
Thermo Fisher Scientific, Waltham, MA, USA). RNA was transcribed into cDNA using a TaKaRa cDNA
Synthesis Kit (Takara Bio INC., Kyoto, Japan) following manufacturer´s instructions. The cDNA was
stored at −20 ◦C. qPCR was performed in 96 well real time pPCR fast plates (7500 Fast Real-Time
PCR System, Life Technologies). A master mix containing 10 µL SYBR Green (Life Technologies),
8 µLRNAse free water and 1 ng of cDNA was added to each well. The forward and reverse primers
(Table S1) were added at a concentration of 10 pg/mL. Then the plate was covered with an adhesive
film (Applied Biosystems, Thermo Fisher Scientific) and centrifuged at 1000 rcf for 1 min at 4 ◦C
(Centrifuge 5417 R Eppendorf, Wesseling-Berzdorf, Germany). TBP (Tata box binding protein) was
used as house-keeping gene [28]. We provide the raw qPCR values in data suppliment.
4.11. Organotypic Brain Slices
All working steps were carried out after all used material was disinfected with 70% ethylalcohol
(EtOH) for at least 30 min. The brain slices were obtained from 13- to 16-day-old C57/Bl6 wild type mice.
The mice were sacrificed by cervical dislocation and decapitated, brains were carefully removed and
immediately transferred to ice cold PBS. The cerebellum and olfactory bulbs were cut off. The brain was
glued (UHU Sekundenkleber, UHU GmbH and Co. KG, Bühl, Germany) in an upward position with its
caudal end to the cutting table of the vibratome (MicrotomHM 650 V, Thermo Scientific) and its ventral
end to an already fixed 5% Agar-Agar block (KobeI, Roth, Karlsruhe, Germany). The cutting table was
fixed in a cooled cutting chamber and covered with ice cold PBS. A vibratome was used to cut the brain
into 250 µm slices. The slices were directly transferred with a glass pipette to ice cold Hanks’ Balanced
Salt Solution (HBSS) (Thermo Fisher Scientific). Up to 3 brain slices were plated on one semi-permeable
membrane insert (Falcon cell culture inserts, 0.4 µm pore size, Corning Life Sciences, Amsterdam,
The Netherlands) in a 6-well plate filled with 1 mL complete growth medium. Red fluorescent GL261
glioma cells were grown confluent and harvested. The cells were further concentrated up to 10,000/µL
and 1 µL drawn up into a Hamilton 1 µL precision Syringe (Microliter Syringe Model Model 701 RN
SYR, Hamiltion Company, Bonaduz, Switzerland) with micro needle. The syringe was attached to
a customized micromanipulator. Twenty-four hours after preparing the murine brain slices, the culture
inserts were transferred to a working 6-well plate equipped with a micromanipulator. All working
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steps were performed at 37 ◦C in complete growth medium. The precision syringe was adjusted
250 µm above the culture insert membrane and the brain slices were positioned. Then, 10,000 mCherry
GL261 cells were injected into the region of basal ganglia in a depth of 150 µm by slowly pushing the
plunger. During injection the syringe was slowly moved upwards. The mCherry GL261 cells were
injected over a range of 50 µm. After injections of red fluorescent GL261, the culture inserts were
transferred to a new plate filled with culture medium containing different concentrations of O-Vanillin.
The brain slices were incubated for 5 days. The medium was renewed every two days.
4.12. Fixation of Brain Slices
Brain slices were fixed with 4% paraformaldehyde (Thermo Fisher Scientific, Paraformaldehyde,
Methanol-free) for 1 h and the cell nuclei were stained with blue fluorescent dye Hoechst (Thermo Fisher
Scientific, Hoechst 33,342 Solution) for 30 min at room temperature. After the brain slices were
carefully cut out from the insert membrane and transferred on microscopy slides, mounted with
Aqua-Poly/Mount (Polysciences, Inc., Aqua-Poly/Mount) and covered with coverslip.
4.13. Microscopy
All micrographs were taken using a Zeiss LSM 710 confocal microscope (Carl Zeiss,
Oberkochen, Germany) with a 20× objective. Injected mCherry GL261 gliomas were visualized
by excitation wavelength 550 nm and emission wavelength 645 nm and further analyzed at the depth
of maximal surface area.
4.14. Tumor Size Measurements
The tumour area and volume were calculated using Imaris 8 software (Version 9.5.0, Bitplane Inc.,
St. Paul, MN, USA). Tumor volumes of high-resolution Zeiss LSM 710 confocal microscopy stacks were
3D rendered by application of 1 µm object detail, 15 threshold background and 1000 tridimensional
pixels (voxels). The surface objects obtained were unified in one single object, and volume mean values
were extracted.
4.15. Statistical Analysis
All analyses were performed using Prism Graphpad (Version 8.4.1, GraphPad Software, San Diego,
CA, USA) and Microsoft Excel 2016. Statistically significant differences were determined with the
Student´s t-test for parametric testing. One-way ANOVA was used to compare multiple groups with
Bonferroni post-hoc test. Significance was defined at p values < 0.05 (*), <0.01 (**) and <0.001 (***).
Supplementary Materials: The following are available online at http://www.mdpi.com/1422-0067/21/8/2959/s1.
Figure S1: Treatment with O-Vanillin does not affect the cell death of microglial cells; Table S1: List of primers.
Supplimental material 1: raw qPCR data.
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